Brokerages Set Urogen Pharma (NASDAQ:URGN) Target Price at $41.62

Urogen Pharma (NASDAQ:URGN) has received an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $41.6250.

A number of research firms have recently issued reports on URGN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Friday, July 17th. Guggenheim boosted their price target on shares of Urogen Pharma from $32.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Oppenheimer boosted their price target on shares of Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. HC Wainwright reaffirmed a “buy” rating on shares of Urogen Pharma in a research note on Thursday, July 9th. Finally, Jefferies Financial Group upgraded shares of Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th.

Insider Activity

In other news, insider Mark Schoenberg sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the insider directly owned 119,763 shares in the company, valued at $4,790,520. This represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,222 shares of company stock valued at $892,661 in the last ninety days. 4.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Urogen Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in URGN. Paradigm Biocapital Advisors LP increased its stake in shares of Urogen Pharma by 6.1% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,473,648 shares of the company’s stock worth $104,773,000 after acquiring an additional 257,564 shares during the last quarter. Morgan Stanley boosted its position in shares of Urogen Pharma by 1.4% during the 4th quarter. Morgan Stanley now owns 2,562,901 shares of the company’s stock valued at $60,023,000 after acquiring an additional 34,455 shares during the last quarter. Soleus Capital Management L.P. acquired a new position in shares of Urogen Pharma during the 2nd quarter valued at about $29,934,000. SG Americas Securities LLC grew its holdings in shares of Urogen Pharma by 20.3% in the first quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company’s stock valued at $29,808,000 after purchasing an additional 280,199 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Urogen Pharma during the fourth quarter worth about $26,350,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

Urogen Pharma Price Performance

Shares of NASDAQ:URGN opened at $38.24 on Wednesday. Urogen Pharma has a 1 year low of $15.86 and a 1 year high of $43.93. The firm has a market capitalization of $1.86 billion, a PE ratio of -13.91 and a beta of 1.56. The business’s 50 day moving average price is $34.98 and its 200-day moving average price is $26.29.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.01. The firm had revenue of $50.96 million during the quarter, compared to analyst estimates of $44.83 million. As a group, analysts expect that Urogen Pharma will post -0.76 earnings per share for the current year.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.